Thrombosis最新文献_第6页

Reversible crystallization of argatroban after subcutaneous application in pigs. 猪皮下应用阿加曲班后可逆结晶。

Thrombosis Pub Date : 2012-01-01 Epub Date: 2012-09-03 DOI: 10.1155/2012/560513

Mercedes Lopez, Goetz Nowak

{"title":"Reversible crystallization of argatroban after subcutaneous application in pigs.","authors":"Mercedes Lopez, Goetz Nowak","doi":"10.1155/2012/560513","DOIUrl":"https://doi.org/10.1155/2012/560513","url":null,"abstract":"Argatroban is a thrombin inhibitor used as anticoagulant in patients with heparin-induced thrombocytopenia. It is usually administered as an intravenous bolus followed by infusion. Nevertheless, its pharmacokinetics after subcutaneous administration is unknown. The aim of this study was to assess the pharmacokinetics of two different formulations of argatroban in pigs after subcutaneous administration. Antithrombotic activity in plasma was determined by ecarin chromogenic assay. To visualize the formation of crystals, argatroban was administered to rats into the subcutaneous tissue exposed after removing the skin, and the injection site was photographed at different times. After subcutaneous administration of a sorbitol/ethanol formulation of argatroban in pigs was observed a slow absorption phase was followed by long-lasting levels of this inhibitor. C(max) and AUC((0-24)) showed dose-dependent increases, while elimination half-life and t(max) value did not change significantly with dose. In contrast, saline-dissolved argatroban showed a faster absorption phase followed by a shorter elimination half-life. Argatroban dissolved in sorbitol/ethanol leads to long-lasting plasma levels due to the formation and permanent dissolution of a crystalline depot at the injection place. This represents a simple way to deliver argatroban continuously over an extended period which can be beneficial for prophylaxis or treatment of chronic coagulations disorders.","PeriodicalId":75222,"journal":{"name":"Thrombosis","volume":"2012 ","pages":"560513"},"PeriodicalIF":0.0,"publicationDate":"2012-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1155/2012/560513","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"30914471","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 1

Factor v leiden and inflammation. 因子v和炎症。

Thrombosis Pub Date : 2012-01-01 Epub Date: 2012-05-14 DOI: 10.1155/2012/594986

Silvia Perez-Pujol, Omer Aras, Gines Escolar

{"title":"Factor v leiden and inflammation.","authors":"Silvia Perez-Pujol, Omer Aras, Gines Escolar","doi":"10.1155/2012/594986","DOIUrl":"https://doi.org/10.1155/2012/594986","url":null,"abstract":"Factor V Leiden, is a variant of human factor V (FV), also known as proaccelerin, which leads to a hypercoagulable state. Along these years, factor V Leiden (FVL) has been studied from the pathophysiologic point of view, and research has been focused on finding clinical approaches for the management of the FVL associated to a trombophilic state. Less attention has been paid about the possible role of FVL in inflammatory conditions known to be present in different disorders such as uremia, cirrhosis, liver transplantation, depression as well as sepsis, infection or, inflammatory bowel disease (IBD). Whether platelet FVL will increase the activation of coagulation and/or in which proportion is able to determine the final outcome in the previously mentioned inflammatory conditions is a subject that remains uncertain. This paper will review the association of FVL with inflammation. Specifically, it will analyze the important role of the endothelium and the contribution of other inflammatory components involved at both the immune and vascular levels. This paper will also try to emphasize the importance of being a FVL carrier in associations to diseases where a chronic inflammation occurs, and how this condition may be determinant in the progression and outcome of a specific clinic situation.","PeriodicalId":75222,"journal":{"name":"Thrombosis","volume":"2012 ","pages":"594986"},"PeriodicalIF":0.0,"publicationDate":"2012-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1155/2012/594986","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"30665945","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 16

Thromboembolic prophylaxis in total joint arthroplasty. 全关节置换术中的血栓栓塞预防。

Thrombosis Pub Date : 2012-01-01 Epub Date: 2012-09-16 DOI: 10.1155/2012/837896

David Knesek, Todd C Peterson, David C Markel

引用次数: 28

Factor V-Leiden Mutation: A Common Risk Factor for Venous Thrombosis among Lebanese Patients. 因子V-Leiden突变:黎巴嫩患者静脉血栓形成的常见危险因素。

Thrombosis Pub Date : 2012-01-01 Epub Date: 2012-06-12 DOI: 10.1155/2012/380681

Raghid Kreidy

{"title":"Factor V-Leiden Mutation: A Common Risk Factor for Venous Thrombosis among Lebanese Patients.","authors":"Raghid Kreidy","doi":"10.1155/2012/380681","DOIUrl":"https://doi.org/10.1155/2012/380681","url":null,"abstract":"Aim. Lebanon exhibits one of the highest prevalences of factor V-Leiden (FVL) in the world (14.4%). The aim of this study is to evaluate the incidence of FVL mutation among Lebanese patients with lower extremity venous thrombosis. Material and Methods. From January 2003 to January 2011, 283 consecutive Lebanese patients, diagnosed with deep venous thrombosis (DVT) by duplex scan, were retrospectively reviewed. FVL mutation was tested among patients with conditions highly suggestive of hypercoagulation states (65 patients). Results. FVL mutation was detected among 56.9% of patients, 68.6% of patients younger than 50 years, and 43.4% of patients older than 50 years (P = 0.041). FVL mutation was commonly reported in young adults, in patients with pregnancy, estrogen drugs, recurrent DVT, and resistance to anticoagulation. Conclusion. The high rate of FVL mutation observed among Lebanese patients with venous thrombosis is related to the high prevalence of this mutation in the Lebanese population. Thrombophilia screening should be tailored to accommodate a population's risk factor. In countries with high prevalence of FVL, this mutation should be screened among patients younger than 50 years and patients with situations highly suggestive of hypercoagulation states.","PeriodicalId":75222,"journal":{"name":"Thrombosis","volume":"2012 ","pages":"380681"},"PeriodicalIF":0.0,"publicationDate":"2012-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1155/2012/380681","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"30721615","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 14

Postthrombotic syndrome: surgical possibilities. 血栓形成后综合征:手术的可能性。

Thrombosis Pub Date : 2012-01-01 Epub Date: 2011-10-31 DOI: 10.1155/2012/520604

Ajay K Khanna, Shivanshu Singh

引用次数: 29

Stroke prevention in atrial fibrillation: understanding the new oral anticoagulants dabigatran, rivaroxaban, and apixaban. 房颤卒中预防:了解新的口服抗凝剂达比加群、利伐沙班和阿哌沙班。

Thrombosis Pub Date : 2012-01-01 Epub Date: 2012-09-10 DOI: 10.1155/2012/108983

Tan Ru San, Mark Yan Yee Chan, Teo Wee Siong, Tang Kok Foo, Ng Kheng Siang, Sze Huar Lee, Ching Chi Keong

{"title":"Stroke prevention in atrial fibrillation: understanding the new oral anticoagulants dabigatran, rivaroxaban, and apixaban.","authors":"Tan Ru San, Mark Yan Yee Chan, Teo Wee Siong, Tang Kok Foo, Ng Kheng Siang, Sze Huar Lee, Ching Chi Keong","doi":"10.1155/2012/108983","DOIUrl":"10.1155/2012/108983","url":null,"abstract":"Unlike vitamin K antagonists (VKAs), the new oral anticoagulants (NOACs)-direct thrombin inhibitor, dabigatran, and direct activated factor X inhibitors, rivaroxaban, and apixaban-do not require routine INR monitoring. Compared to VKAs, they possess relatively rapid onset of action and short halflives, but vary in relative degrees of renal excretion as well as interaction with p-glycoprotein membrane transporters and liver cytochrome P450 metabolic enzymes. Recent completed phase III trials comparing NOACs with VKAs for stroke prevention in atrial fibrillation (AF)-the RE-LY, ROCKET AF, and ARISTOTLE trials-demonstrated at least noninferior efficacy, largely driven by significant reductions in haemorrhagic stroke. Major and nonmajor clinically relevant bleeding rates were acceptable compared to VKAs. Of note, the NOACs caused significantly less intracranial haemorrhagic events compared to VKAs, the mechanisms of which are not completely clear. With convenient fixed-dose administration, the NOACs facilitate anticoagulant management in AF in the community, which has hitherto been grossly underutilised. Guidelines should evolve towards simplicity in anticipation of greater use of NOACs among primary care physicians. At the same time, the need for caution with their use in patients with severely impaired renal function should be emphasised.","PeriodicalId":75222,"journal":{"name":"Thrombosis","volume":"2012 ","pages":"108983"},"PeriodicalIF":0.0,"publicationDate":"2012-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1155/2012/108983","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"30921945","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 19

Cerebral vein thrombosis misdiagnosed and mismanaged. 脑静脉血栓的误诊和治疗不当。

Thrombosis Pub Date : 2012-01-01 Epub Date: 2012-04-05 DOI: 10.1155/2012/210676

P K Sasidharan

{"title":"Cerebral vein thrombosis misdiagnosed and mismanaged.","authors":"P K Sasidharan","doi":"10.1155/2012/210676","DOIUrl":"https://doi.org/10.1155/2012/210676","url":null,"abstract":"Cerebral venous thrombosis (CVT) should be considered in the differential diagnosis of all unexplained CNS disorders of sudden onset. Etiological factors are often subclinical forms of several common thrombophilic states occurring together, rather than the typical inherited and rare causes. Diagnosis is missed because of the heterogeneity in clinical presentation and etiological factors. In several patients with the so called idiopathic CVT nutritional deficiencies and lifestyle issues are more important factors in pathogenesis, rather than single rarer causes. High index of suspicion is the key to diagnosis. Clinical skill has to be fine tuned to diagnose the problem and to identify all the etiological factors. Radiology is essential for diagnosis but relying on radiology alone will lead to missing several cases and even erroneous diagnosis. It is inappropriate to proceed prematurely to laboratory investigations, forgetting proper clinical evaluation by studying diet, lifestyle, and environment of the patients. Success in managing lies in identifying all the contributory causes and correcting all of them giving excellent outcome almost always. Clinical observations based on case series and sharing of such information alone are the means to arrive at a consensus in diagnosis and management.","PeriodicalId":75222,"journal":{"name":"Thrombosis","volume":"2012 ","pages":"210676"},"PeriodicalIF":0.0,"publicationDate":"2012-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1155/2012/210676","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"30602100","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 46

Actual situation of thromboembolic prophylaxis in obesity surgery: data of quality assurance in bariatric surgery in Germany. 肥胖手术中血栓栓塞预防的实际情况:德国减肥手术质量保证数据。

Thrombosis Pub Date : 2012-01-01 Epub Date: 2012-07-09 DOI: 10.1155/2012/209052

Christine Stroh, D Luderer, R Weiner, T Horbach, K Ludwig, F Benedix, Stefanie Wolff, C Knoll, H Lippert, T Manger

{"title":"Actual situation of thromboembolic prophylaxis in obesity surgery: data of quality assurance in bariatric surgery in Germany.","authors":"Christine Stroh, D Luderer, R Weiner, T Horbach, K Ludwig, F Benedix, Stefanie Wolff, C Knoll, H Lippert, T Manger","doi":"10.1155/2012/209052","DOIUrl":"https://doi.org/10.1155/2012/209052","url":null,"abstract":"Background. Evidence-based data on optimal approach for prophylaxis of deep venous thrombosis (VTE) and pulmonary embolism (PE) in bariatric operations is discussed. Using antithrombotic prophylaxis weight adjusted the risk of VTE and its complications have to be balanced with the increased bleeding risk. Methods. Since 2005 the current situation for bariatric surgery has been examined by quality assurance study in Germany. As a prospective multicenter observational study, data on the type, regimen, and time course of VTE prophylaxis were documented. The incidences of clinically diagnosed VTE or PE were derived during the in-hospital course and follow up. Results. Overall, 11,835 bariatric procedures were performed between January 2005 and December 2010. Most performed procedures were 2730 gastric banding (GB); 4901 Roux-en-Y-gastric bypass (RYGBP) procedures, and 3026 sleeve gastrectomies (SG). Study collective includes 72.5% (mean BMI 48.1 kg/m(2)) female and 27.5% (mean BMI 50.5 kg/m(2)) male patients. Incidence of VTE was 0.06% and of PE 0.08%. Conclusion. VTE prophylaxis regimen depends on BMI and the type of procedure. Despite the low incidence of VTE and PE there is a lack of evidence. Therefore, prospective randomized studies are necessary to determine the optimal VTE prophylaxis for bariatric surgical patients.","PeriodicalId":75222,"journal":{"name":"Thrombosis","volume":"2012 ","pages":"209052"},"PeriodicalIF":0.0,"publicationDate":"2012-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3400389/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"30801968","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 13

Management of venous thromboembolism in patients with advanced gastrointestinal cancers: what is the role of novel oral anticoagulants? 晚期胃肠癌患者静脉血栓栓塞的治疗:新型口服抗凝剂的作用是什么?

Thrombosis Pub Date : 2012-01-01 Epub Date: 2012-09-11 DOI: 10.1155/2012/758385

Ludmila Katherine Martin, Tanios Bekaii-Saab

引用次数: 17

Towards personalized medicine based on platelet function testing for stent thrombosis patients. 基于血小板功能检测的支架血栓患者个体化用药研究。

Thrombosis Pub Date : 2012-01-01 Epub Date: 2012-12-25 DOI: 10.1155/2012/617098

Thea Cornelia Godschalk, Christian Marcus Hackeng, Jurriën Maria Ten Berg

{"title":"Towards personalized medicine based on platelet function testing for stent thrombosis patients.","authors":"Thea Cornelia Godschalk, Christian Marcus Hackeng, Jurriën Maria Ten Berg","doi":"10.1155/2012/617098","DOIUrl":"https://doi.org/10.1155/2012/617098","url":null,"abstract":"Stent thrombosis (ST) is a severe and feared complication of coronary stenting. Patients who have suffered from ST are usually treated according to the \"one-size-fits-all\" dosing regimen of aspirin and clopidogrel. Many ST patients show high on-treatment platelet reactivity (HPR) despite this antiplatelet therapy (APT). It has been shown that HPR is a risk factor for major adverse cardiac events. Therefore, ST patients with HPR are at a high risk for recurrent atherothrombotic events. New insights into the variable response to clopidogrel and the advent of stronger P2Y12 inhibitors prasugrel and ticagrelor have changed the attention from a fixed APT treatment strategy towards \"personalized APT strategies.\" Strategies can be based on platelet function testing, which gives insight into the overall response of a patient to APT. At our outpatient ST clinic, we practice personalized APT based on platelet function testing to guide the cardiologist to a presumed optimal antiplatelet treatment of ST patients. Beside results of platelet function testing, comedication, clinical characteristics, and genetics have to be considered to decide on personalized APT. Ongoing studies have yet to reveal the optimal personalized APT strategy for cardiologists to prevent their patients from atherothrombotic and bleeding events.","PeriodicalId":75222,"journal":{"name":"Thrombosis","volume":"2012 ","pages":"617098"},"PeriodicalIF":0.0,"publicationDate":"2012-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1155/2012/617098","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"31158733","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 7